Chromosome studies in human unfertilized oocytes and uncleaved zygotes after treatment with gonadotropin-releasing hormone analogs.
OBJECTIVE
To determine the frequency of the anomalies from the cytogenetic point of view in the oocytes remaining from our in vitro fertilization (IVF) program. Two gonadotropin-releasing hormone analogs (GnRH-a) were used (buserelin acetate and leuprolide acetate) in the superovulation treatment.


METHODS
A prospective study was planned in January 1989. Deadline for data and quantitative analysis was to be July 1990.


METHODS
Hospital de Cruces, a public and tertiary institute.


METHODS
One hundred thirty-nine IVF patients, yielding 433 oocytes. Selected on the basis of availability of oocytes and staff.


RESULTS
Two hundred thirty-eight oocytes (71.25%) exhibited the normal number of metaphase II chromosomes; 64 (19.16%) exhibited aneuploidy; 13 (3.89%) were diploid, hyperdiploid, or hypodiploid; and 19 (5.68%) showed parthenogenetic activation. Of the 99 zygotes, 17 were polyploid and 48 showed prematurely condensed chromosomes, whereas in 31 cases the male and female pronuclei remained separate.


CONCLUSIONS
It would not appear that the rate of chromosomal anomalies is affected after pituitary suppression with GnRH-a.
Tejada
M I
MI
Department of Obstetrics and Gynecology, Hospital de Cruces, Vizcaya, Spain.
Mendoza
R
R
Corcóstegui
B
B
Benito
J A
JA
D000328:Adult; D002064:Buserelin / Q000494:pharmacology; D002874:Chromosome Mapping; D002970:Cleavage Stage, Ovum; D005260:Female; D005306:Fertilization; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000502:physiology*; D011003:Ploidies; D015053:Zygote / Q000187:drug effects / Q000502:physiology*
D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; D002064:Buserelin